
## Ralitza Gueorguieva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7633537/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Change in impulsivity is prospectively associated with treatment outcomes for binge-eating disorder. Psychological Medicine, 2023, 53, 2789-2797.	2.7	5
2	Dynamic structural equation modeling of the relationship between alcohol habit and drinking variability. Drug and Alcohol Dependence, 2022, 233, 109202.	1.6	1
3	Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory <sup>11</sup> Câ€UCBâ€J positron emission tomography study in humans. Addiction Biology, 2022, 27, e13123.	1.4	16
4	Reducing the Duration of Untreated Psychosis (DUP) in a US Community: A Quasi-Experimental Trial. Schizophrenia Bulletin Open, 2022, 3, sgab057.	0.9	22
5	Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology, 2022, 47, 1574-1581.	2.8	41
6	mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. Journal of Affective Disorders, 2022, 303, 91-97.	2.0	22
7	Novel nicotine concentration labels improve adolescents' and young adults' understanding of the nicotine strength of electronic nicotine delivery system products. Nicotine and Tobacco Research, 2022, , .	1.4	Ο
8	Corrigendum to: Reducing the Duration of Untreated Psychosis (DUP) in a US Community: A Quasi-Experimental Trial. Schizophrenia Bulletin Open, 2022, 3, .	0.9	0
9	Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science. Addiction Biology, 2022, 27, e13161.	1.4	3
10	Plasma Menthol Glucuronide as a Biomarker for the Behavioral Effects of Menthol and Nicotine in Humans. Frontiers in Pharmacology, 2022, 13, 844824.	1.6	0
11	Prefrontal Glutamate Neurotransmission in PTSD: A Novel Approach to Estimate Synaptic Strength in Vivo in Humans. Chronic Stress, 2022, 6, 247054702210927.	1.7	8
12	Longitudinal Trajectories of Multiple Nicotine Product Use Among Youths in the Population Assessment of Tobacco and Health Study. JAMA Network Open, 2022, 5, e223549.	2.8	3
13	Sensitivity, specificity, and tolerability of the BACTrack <i>Skyn</i> compared to other alcohol monitoring approaches among young adults in a fieldâ€based setting. Alcoholism: Clinical and Experimental Research, 2022, 46, 783-796.	1.4	8
14	Development of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans. Psychopharmacology, 2022, 239, 2809-2818.	1.5	0
15	Predictors of abstinence, no heavy drinking days, and a 2â€level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study. Alcoholism: Clinical and Experimental Research, 2022, 46, 1331-1339.	1.4	1
16	Clinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic. JAMA Network Open, 2022, 5, e2216349.	2.8	11
17	Smoking history and the association between alcohol and eâ€cigarette use: authors' reply. Addiction, 2021, 116, 971-972.	1.7	0
18	NaltrexoneÂ+ Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: AÂRandomized, Controlled Pilot Study. Clinical Therapeutics, 2021, 43, 112-122.e1.	1.1	25

#	Article	IF	CITATIONS
19	Trends in various e-cigarette devices used by high school adolescents from 2017-2019. Drug and Alcohol Dependence, 2021, 219, 108497.	1.6	16
20	Randomized Controlled Trial of Treatments for Lossâ€of ontrol Eating Following Bariatric Surgery. Obesity, 2021, 29, 689-697.	1.5	12
21	Mapping dataâ€driven individualized neurobehavioral phenotypes in heavy alcohol drinkers. Alcoholism: Clinical and Experimental Research, 2021, 45, 841-853.	1.4	3
22	Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers. Psychopharmacology, 2021, 238, 2083-2090.	1.5	6
23	Sex differences in progestogen- and androgen-derived neurosteroids in vulnerability to alcohol and stress-related disorders. Neuropharmacology, 2021, 187, 108499.	2.0	8
24	Examining depression scores as predictors and moderators of treatment outcomes in patients with bingeâ€eating disorder. International Journal of Eating Disorders, 2021, 54, 1555-1559.	2.1	2
25	Smartband-Based Automatic Smoking Detection and Real-time Mindfulness Intervention: Protocol for a Feasibility Trial. JMIR Research Protocols, 2021, 10, e32521.	0.5	6
26	Association of Vaping and Respiratory Health among Youth in the Population Assessment of Tobacco and Health (PATH) Study Wave 3. International Journal of Environmental Research and Public Health, 2021, 18, 8208.	1.2	6
27	Influence of menthol and green apple e-liquids containing different nicotine concentrations among youth e-cigarette users Experimental and Clinical Psychopharmacology, 2021, 29, 355-365.	1.3	16
28	Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants. Frontiers in Psychiatry, 2021, 12, 709559.	1.3	2
29	STRONG STAR and the Consortium to Alleviate PTSD: Shaping the future of combat PTSD and related conditions in military and veteran populations. Contemporary Clinical Trials, 2021, 110, 106583.	0.8	15
30	The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials. Addictive Behaviors, 2021, 122, 106970.	1.7	3
31	Detecting change in psychiatric functioning in clinical trials for cocaine use disorder: sensitivity of the Addiction Severity Index and Brief Symptom Inventory. Drug and Alcohol Dependence, 2021, 228, 109070.	1.6	2
32	Acute effects of inhaled menthol on cognitive effects of intravenous nicotine among young adult cigarette smokers. Addictive Behaviors, 2021, 122, 107022.	1.7	1
33	The effects of inhaled flavors on intravenous nicotine Experimental and Clinical Psychopharmacology, 2021, 29, 615-624.	1.3	6
34	Examining Self-Weighing Behaviors and Associated Features and Treatment Outcomes in Patients with Binge-Eating Disorder and Obesity with and without Food Addiction. Nutrients, 2021, 13, 29.	1.7	6
35	Models for Analyzing Zero-Inflated and Overdispersed Count Data: An Application to Cigarette and Marijuana Use. Nicotine and Tobacco Research, 2020, 22, 1390-1398.	1.4	39
36	Modulation of "Protective―Nicotine Perception and Use Profile by Flavorants: Preliminary Findings in E-cigarettes. Nicotine and Tobacco Research, 2020, 22, 771-781.	1.4	26

#	Article	IF	CITATIONS
37	Craving to Quit: A Randomized Controlled Trial of Smartphone App–Based Mindfulness Training for Smoking Cessation. Nicotine and Tobacco Research, 2020, 22, 324-331.	1.4	112
38	Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial. Neuropsychopharmacology, 2020, 45, 319-326.	2.8	8
39	The Association of Impulsivity and Family History of Alcohol Use Disorder on Alcohol Use and Consequences. Alcoholism: Clinical and Experimental Research, 2020, 44, 159-167.	1.4	17
40	Histopathologyâ€guided mass spectrometry differentiates benign nevi from malignant melanoma. Journal of Cutaneous Pathology, 2020, 47, 226-240.	0.7	16
41	Transitions across tobacco use profiles among adolescents: results from the Population Assessment of Tobacco and Health (PATH) study waves 1 and 2. Addiction, 2020, 115, 740-747.	1.7	13
42	Examining sex as a predictor and moderator of treatment outcomes for bingeâ€eating disorder: Analysis of aggregated randomized controlled trials. International Journal of Eating Disorders, 2020, 53, 20-30.	2.1	9
43	Twoâ€part models for repeatedly measured ordinal data with "don't know―category. Statistics in Medicine, 2020, 39, 4574-4592.	0.8	0
44	An integrated behavioural intervention combined with varenicline for heavy-drinking smokers: a randomized pilot study. Journal of Smoking Cessation, 2020, 15, 119-127.	0.3	4
45	Randomized Controlled Trial of Behavioral Weight Loss and Stepped Care for Bingeâ€Eating Disorder: 12â€Month Followâ€up. Obesity, 2020, 28, 2116-2124.	1.5	19
46	Using an adoption design to test genetically based differences in risk for child behavior problems in response to home environmental influences. Development and Psychopathology, 2020, 33, 1-19.	1.4	4
47	Data Visualization Tools of Tobacco Product Use Patterns, Transitions and Sex Differences in the PATH Youth Data. Nicotine and Tobacco Research, 2020, 22, 1901-1908.	1.4	4
48	Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology, 2020, 45, 990-997.	2.8	127
49	Prospective association of eâ€cigarette and cigarette use with alcohol use in two waves of the Population Assessment of Tobacco and Health. Addiction, 2020, 115, 1571-1579.	1.7	15
50	Systematic review and metaâ€analysis of the moderating effect of rs1799971 in <i>OPRM1</i> , the muâ€opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction, 2020, 115, 1426-1437.	1.7	27
51	Differential effects of nicotine delivery rate on subjective drug effects, urges to smoke, heart rate and blood pressure in tobacco smokers. Psychopharmacology, 2020, 237, 1359-1369.	1.5	10
52	Randomized controlled trial testing the effectiveness of adaptive "SMART―stepped-care treatment for adults with binge-eating disorder comorbid with obesity American Psychologist, 2020, 75, 204-218.	3.8	48
53	Kratom and Pain Tolerance: A Randomized, Placebo-Controlled, Double-Blind Study. Yale Journal of Biology and Medicine, 2020, 93, 229-238.	0.2	18
54	Tobacco use increases risk of food insecurity: An analysis of continuous NHANES data from 1999 to 2014. Preventive Medicine, 2019, 126, 105765.	1.6	14

#	Article	IF	CITATIONS
55	Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study. Neuropsychopharmacology, 2019, 44, 2112-2118.	2.8	57
56	Adolescents' awareness of the nicotine strength and e-cigarette status of JUUL e-cigarettes. Drug and Alcohol Dependence, 2019, 204, 107512.	1.6	56
57	Implementing Motivational Interviewing for Substance Misuse on Medical Inpatient Units: a Randomized Controlled Trial. Journal of General Internal Medicine, 2019, 34, 2520-2529.	1.3	15
58	Altered functional connectivity and low-frequency signal fluctuations in early psychosis and genetic high risk. Schizophrenia Research, 2019, 210, 172-179.	1.1	17
59	Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology, 2019, 44, 1233-1238.	2.8	35
60	Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. Contemporary Clinical Trials, 2019, 81, 11-18.	0.8	26
61	Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking. Alcoholism: Clinical and Experimental Research, 2019, 43, 937-944.	1.4	14
62	Targeting neuroinflammation with minocycline in heavy drinkers. Psychopharmacology, 2019, 236, 3013-3021.	1.5	20
63	An Open Trial of Intensive Cognitive-Behavioral Therapy for School Refusal. Evidence-Based Practice in Child and Adolescent Mental Health, 2019, 4, 89-101.	0.7	9
64	Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder. Alcoholism: Clinical and Experimental Research, 2019, 43, 741-746.	1.4	11
65	Sleep improvements and associations with default mode network functional connectivity following rTMS for generalized anxiety disorder. Brain Stimulation, 2019, 12, 184-186.	0.7	6
66	Examining race as a predictor and moderator of treatment outcomes for binge-eating disorder: Analysis of aggregated randomized controlled trials Journal of Consulting and Clinical Psychology, 2019, 87, 530-540.	1.6	17
67	A fMRI study on the impact of advertising for flavored e-cigarettes on susceptible young adults. Drug and Alcohol Dependence, 2018, 186, 233-241.	1.6	35
68	Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. Biological Psychiatry, 2018, 84, 413-421.	0.7	43
69	Posttraumatic stress disorder diagnosis and gender are associated with accelerated weight gain trajectories in veterans during the post-deployment period. Eating Behaviors, 2018, 29, 8-13.	1.1	18
70	Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking. JAMA Psychiatry, 2018, 75, 129.	6.0	79
71	Mecamylamine treatment for alcohol dependence: a randomized controlled trial. Addiction, 2018, 113, 6-14.	1.7	23
72	Incidence of second solid cancers in mastocytosis patients: a SEER database analysis. Leukemia and Lymphoma, 2018, 59, 1474-1477.	0.6	5

#	Article	IF	CITATIONS
73	Bayesian joint modelling of longitudinal data on abstinence, frequency and intensity of drinking in alcoholism trials. Journal of the Royal Statistical Society Series A: Statistics in Society, 2018, 181, 869-888.	0.6	3
74	Impact of E-cigarettes on Smoking and Related Outcomes in Veteran Smokers With Psychiatric Comorbidity. Journal of Dual Diagnosis, 2018, 14, 2-13.	0.7	19
75	Physical activity and mental health – Author's reply. Lancet Psychiatry,the, 2018, 5, 874.	3.7	7
76	Acute effects of inhaled menthol on the rewarding effects of intravenous nicotine in smokers. Journal of Psychopharmacology, 2018, 32, 986-994.	2.0	13
77	Predicting Barriers to Treatment for Depression in a U.S. National Sample: A Cross-Sectional, Proof-of-Concept Study. Psychiatric Services, 2018, 69, 927-934.	1.1	31
78	Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer. Journal of Smoking Cessation, 2018, 13, 244-247.	0.3	5
79	Association between physical exercise and mental health in 1·2 million individuals in the USA between 2011 and 2015: a cross-sectional study. Lancet Psychiatry,the, 2018, 5, 739-746.	3.7	658
80	Plasma Menthol Glucuronide as a Biomarker of Acute Menthol Inhalation. Tobacco Regulatory Science (discontinued), 2018, 4, 586-591.	0.2	8
81	A Multisite Benchmarking Trial of Capnometry Guided Respiratory Intervention for Panic Disorder in Naturalistic Treatment Settings. Applied Psychophysiology Biofeedback, 2017, 42, 51-58.	1.0	21
82	Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. Lancet Psychiatry,the, 2017, 4, 230-237.	3.7	47
83	Reevaluating the Efficacy and Predictability of Antidepressant Treatments. JAMA Psychiatry, 2017, 74, 370.	6.0	203
84	Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression. Neuropsychopharmacology, 2017, 42, 2482-2492.	2.8	150
85	A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology, 2017, 42, 2567-2574.	2.8	36
86	A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia. Experimental Physiology, 2017, 102, 587-597.	0.9	3
87	Statistical Models for the Analysis of Zero-Inflated Pain Intensity Numeric Rating Scale Data. Journal of Pain, 2017, 18, 340-348.	0.7	22
88	Studying the interactive effects of menthol and nicotine among youth: An examination using e-cigarettes. Drug and Alcohol Dependence, 2017, 180, 193-199.	1.6	46
89	The Influence of Cyclic Hormonal Contraception on Expression of Premenstrual Syndrome. Journal of Women's Health, 2017, 26, 321-328.	1.5	13
90	Longitudinal influence of alcohol and marijuana use on academic performance in college students. PLoS ONE, 2017, 12, e0172213.	1.1	74

Ralitza Gueorguieva

#	Article	IF	CITATIONS
91	Prazosin for Veterans with Posttraumatic Stress Disorder and Comorbid Alcohol Dependence: A Clinical Trial. Alcoholism: Clinical and Experimental Research, 2016, 40, 178-186.	1.4	94
92	RANDOMIZED TRIAL OF D-CYCLOSERINE ENHANCEMENT OF COGNITIVE-BEHAVIORAL THERAPY FOR PANIC DISORDER. Depression and Anxiety, 2016, 33, 737-745.	2.0	62
93	Improvements in emotion regulation following repetitive transcranial magnetic stimulation for generalized anxiety disorder. Journal of Anxiety Disorders, 2016, 43, 1-7.	1.5	43
94	Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms. Journal of the American Academy of Dermatology, 2016, 75, 1176-1186.e4.	0.6	38
95	Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry,the, 2016, 3, 243-250.	3.7	469
96	Intravenous Nicotine Self-Administration in Smokers: Dose–Response Function and Sex Differences. Neuropsychopharmacology, 2016, 41, 2034-2040.	2.8	29
97	The effects of alcohol-containing e-cigarettes on young adult smokers. Drug and Alcohol Dependence, 2016, 159, 272-276.	1.6	33
98	Longitudinal findings from a randomized clinical trial of naltrexone for young adult heavy drinkers Journal of Consulting and Clinical Psychology, 2016, 84, 185-190.	1.6	10
99	Randomized controlled trial of a very brief, multicomponent web-based alcohol intervention for undergraduates with a focus on protective behavioral strategies Journal of Consulting and Clinical Psychology, 2016, 84, 1008-1015.	1.6	25
100	A modified classification tree method for personalized medicine decisions. Statistics and Its Interface, 2016, 9, 239-253.	0.2	9
101	Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response Journal of Consulting and Clinical Psychology, 2015, 83, 387-394.	1.6	33
102	Predictors of Abstinence From Heavy Drinking During Follow-Up in COMBINE. Journal of Studies on Alcohol and Drugs, 2015, 76, 935-941.	0.6	15
103	See One, Do One, Order One: a study protocol for cluster randomized controlled trial testing three strategies for implementing motivational interviewing on medical inpatient units. Implementation Science, 2015, 10, 138.	2.5	4
104	Reduction of Alcohol Drinking in Young Adults by Naltrexone. Journal of Clinical Psychiatry, 2015, 76, e207-e213.	1.1	67
105	Multidisciplinary Proactive Psychiatric Consultation Service: Impact on Length of Stay for Medical Inpatients. Psychotherapy and Psychosomatics, 2015, 84, 208-216.	4.0	46
106	Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia. Journal of Psychiatric Research, 2015, 61, 64-72.	1.5	50
107	Acute alcohol consumption elevates serum bilirubin: An endogenous antioxidant. Drug and Alcohol Dependence, 2015, 149, 87-92.	1.6	14
108	An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. European Neuropsychopharmacology, 2015, 25, 1586-1599.	0.3	11

#	Article	IF	CITATIONS
109	Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder. JAMA Psychiatry, 2015, 72, 1037.	6.0	53
110	ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 1881-1883.	0.6	9
111	Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study. BMC Psychiatry, 2014, 14, 335.	1.1	74
112	Predictors of Abstinence from Heavy Drinking During Treatment in <scp>COMBINE</scp> and External Validation in <scp>PREDICT</scp> . Alcoholism: Clinical and Experimental Research, 2014, 38, 2647-2656.	1.4	18
113	Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. American Journal on Addictions, 2014, 23, 288-293.	1.3	34
114	A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology, 2014, 231, 939-948.	1.5	69
115	Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: Randomized placebo-controlled clinical trial of self-help and medication. Behaviour Research and Therapy, 2014, 58, 1-9.	1.6	59
116	Rates of violence in patients classified as high risk by structured risk assessment instruments. British Journal of Psychiatry, 2014, 204, 180-187.	1.7	60
117	Self-help for binge eating disorder in primary care: A randomized controlled trial with ethnically and racially diverse obese patients. Behaviour Research and Therapy, 2013, 51, 855-861.	1.6	43
118	Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. Addictive Behaviors, 2013, 38, 2119-2127.	1.7	22
119	The Impact of NMDA Receptor Blockade on Human Working Memory-Related Prefrontal Function and Connectivity. Neuropsychopharmacology, 2013, 38, 2613-2622.	2.8	133
120	Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Molecular Psychiatry, 2013, 18, 1199-1204.	4.1	197
121	Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophrenia Research, 2013, 143, 344-347.	1.1	17
122	DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients. Leukemia Research, 2013, 37, 1445-1450.	0.4	72
123	Predictive significance of the overvaluation of shape/weight in obese patients with binge eating disorder: findings from a randomized controlled trial with 12-month follow-up. Psychological Medicine, 2013, 43, 1335-1344.	2.7	77
124	Random effects models for joint analysis of repeatedly measured discrete and continuous outcomes. , 2013, , 109-123.		1
125	Noradrenergic vs Serotonergic Antidepressant with or without Naltrexone for Veterans with PTSD and Comorbid Alcohol Dependence. Neuropsychopharmacology, 2012, 37, 996-1004.	2.8	104
126	Rapid response predicts 12-month post-treatment outcomes in binge-eating disorder: theoretical and clinical implications. Psychological Medicine, 2012, 42, 807-817.	2.7	50

#	Article	IF	CITATIONS
127	Imaging Mass Spectrometry—A New and Promising Method to Differentiate Spitz Nevi From Spitzoid Malignant Melanomas. American Journal of Dermatopathology, 2012, 34, 82-90.	0.3	103
128	Glutamatergic Modulation of Auditory Information Processing in the Human Brain. Biological Psychiatry, 2012, 71, 969-977.	0.7	73
129	Impaired Visual Cortical Plasticity in Schizophrenia. Biological Psychiatry, 2012, 71, 512-520.	0.7	118
130	Cigarette Smoking Predicts Differential Benefit from Naltrexone for Alcohol Dependence. Biological Psychiatry, 2012, 72, 832-838.	0.7	56
131	Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment. Alcohol, 2012, 46, 121-131.	0.8	20
132	Joint Modelling of Longitudinal Outcome and Interval-Censored Competing Risk Dropout in a Schizophrenia Clinical Trial. Journal of the Royal Statistical Society Series A: Statistics in Society, 2012, 175, 417-433.	0.6	27
133	Using Computational Patients to Evaluate Illness Mechanisms in Schizophrenia. Biological Psychiatry, 2011, 69, 997-1005.	0.7	45
134	Inter-rater reliability and concurrent validity of DSM-IV opioid dependence in a Hmong isolate using the Thai version of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA). Addictive Behaviors, 2011, 36, 156-160.	1.7	26
135	Trajectories of Depression Severity in Clinical Trials of Duloxetine. Archives of General Psychiatry, 2011, 68, 1227.	13.8	106
136	Cognitive–behavioral therapy, behavioral weight loss, and sequential treatment for obese patients with binge-eating disorder: A randomized controlled trial Journal of Consulting and Clinical Psychology, 2011, 79, 675-685.	1.6	282
137	Baseline Trajectories of Drinking Moderate Acamprosate and Naltrexone Effects in the COMBINE Study. Alcoholism: Clinical and Experimental Research, 2011, 35, 523-531.	1.4	19
138	Lateral ventricle volume and psychotic features in adolescents and adults with bipolar disorder. Psychiatry Research - Neuroimaging, 2011, 194, 400-402.	0.9	17
139	Differential changes in body mass index after retirement by occupation: hierarchical models. International Journal of Public Health, 2011, 56, 111-116.	1.0	15
140	The Effect of Early Trauma Exposure on Serotonin Type 1B Receptor Expression Revealed by Reduced Selective Radioligand Binding. Archives of General Psychiatry, 2011, 68, 892.	13.8	84
141	Regulation of cocaine self-administration in humans: Lack of evidence for loading and maintenance phases. Pharmacology Biochemistry and Behavior, 2010, 95, 51-55.	1.3	8
142	Adolescent cannabis use increases risk for cocaine-induced paranoia. Drug and Alcohol Dependence, 2010, 107, 196-201.	1.6	24
143	Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. Drug and Alcohol Dependence, 2010, 107, 221-229.	1.6	44
144	The Impact of Occupation on Self-Rated Health: Cross-Sectional and Longitudinal Evidence from the Health and Retirement Survey. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2009, 64B, 118-124.	2.4	62

#	Article	IF	CITATIONS
145	Length of Prenatal Participation in WIC and Risk of Delivering a Small for Gestational Age Infant: Florida, 1996–2004. Maternal and Child Health Journal, 2009, 13, 479-488.	0.7	18
146	Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis. Behavioural Pharmacology, 2009, 20, 390-399.	0.8	172
147	Absence of Significant Interactive Effects of Highâ€Dose <scp>d</scp> â€Cycloserine and Ethanol in Healthy Human Subjects: Preliminary Insights Into Ethanol Actions at the Clycine <sub>B</sub> Site of NMDA Glutamate Receptors. Alcoholism: Clinical and Experimental Research, 2008, 32, 36-42.	1.4	10
148	Naltrexone Is Associated With Reduced Drinking by Alcohol Dependent Patients Receiving Antidepressants for Mood and Anxiety Symptoms: Results From VA Cooperative Study No. 425, "Naltrexone in the Treatment of Alcoholism― Alcoholism: Clinical and Experimental Research, 2008, 32, 85-91.	1.4	20
149	Dirichlet component regression and its applications to psychiatric data. Computational Statistics and Data Analysis, 2008, 52, 5344-5355.	0.7	44
150	It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists. Biological Psychiatry, 2008, 63, 725-727.	0.7	65
151	Impairment of Working Memory Maintenance and Response in Schizophrenia: Functional Magnetic Resonance Imaging Evidence. Biological Psychiatry, 2008, 64, 1026-1034.	0.7	110
152	Blunted Psychotomimetic and Amnestic Effects of î"-9-Tetrahydrocannabinol in Frequent Users of Cannabis. Neuropsychopharmacology, 2008, 33, 2505-2516.	2.8	225
153	Effect of Memantine on Cue-Induced Alcohol Craving in Recovering Alcohol-Dependent Patients. American Journal of Psychiatry, 2007, 164, 519-523.	4.0	106
154	Cortisol levels in relation to hippocampal sub-regions in subjects with first episode schizophrenia. Schizophrenia Research, 2007, 94, 281-287.	1.1	27
155	Dopamine β-Hydroxylase Gene (DβH) -1021C→T Influences Self-Reported Paranoia during Cocaine Self-Administration. Biological Psychiatry, 2007, 61, 1310-1313.	0.7	58
156	New Insights into the Efficacy of Naltrexone Based on Trajectory-Based Reanalyses of Two Negative Clinical Trials. Biological Psychiatry, 2007, 61, 1290-1295.	0.7	43
157	Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study. Alcoholism: Clinical and Experimental Research, 2007, 31, 070212174136005-???.	1.4	178
158	Antiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam. Alcoholism: Clinical and Experimental Research, 2007, 31, 070212174136008-???.	1.4	103
159	Multidimensionality of the Alcohol Withdrawal Symptom Checklist: A Factor Analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar. Alcoholism: Clinical and Experimental Research, 2007, 31, 070212174136010-???.	1.4	50
160	CSF sub-compartments in relation to plasma osmolality in healthy controls and in patients with first episode schizophrenia. Psychiatry Research - Neuroimaging, 2007, 155, 57-66.	0.9	4
161	Effects of Naltrexone on Cognition in a Treatment Study of Patients with Schizophrenia and Comorbid Alcohol Dependence. Journal of Dual Diagnosis, 2006, 2, 53-69.	0.7	5
162	Cortical Gamma-Aminobutyric Acid Levels and the Recovery from Ethanol Dependence: Preliminary Evidence of Modification by Cigarette Smoking. Biological Psychiatry, 2006, 59, 85-93.	0.7	71

#	Article	IF	CITATIONS
163	Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs. Drug and Alcohol Dependence, 2006, 84, 77-84.	1.6	41
164	Joint analysis of repeatedly observed continuous and ordinal measures of disease severity. Statistics in Medicine, 2006, 25, 1307-1322.	0.8	41
165	Gelatin "Shots" as a New Method for Alcohol Administration in a Laboratory Setting. Alcoholism: Clinical and Experimental Research, 2006, 30, 473-479.	1.4	11
166	Modeling Longitudinal Data. Biometrics, 2006, 62, 944-945.	0.8	0
167	Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. Psychopharmacology, 2006, 186, 425-433.	1.5	111
168	Self-reported paranoia during laboratory "binge―cocaine self-administration in humans. Pharmacology Biochemistry and Behavior, 2006, 83, 249-256.	1.3	39
169	Estradiol and Tryptophan Depletion Interact to Modulate Cognition in Menopausal Women. Neuropsychopharmacology, 2006, 31, 2489-2497.	2.8	43
170	Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism. Neuropsychopharmacology, 2006, 31, 1793-1800.	2.8	48
171	Enhanced Sensitivity to the Euphoric Effects of Alcohol in Schizophrenia. Neuropsychopharmacology, 2006, 31, 2767-2775.	2.8	43
172	Cortical γ-Aminobutyric Acid Type A–Benzodiazepine Receptors in Recovery From Alcohol Dependence. Archives of General Psychiatry, 2005, 62, 877.	13.8	45
173	Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine. Archives of General Psychiatry, 2005, 62, 985.	13.8	295
174	Comments about Joint Modeling of Cluster Size and Binary and Continuous Subunit-Specific Outcomes. Biometrics, 2005, 61, 862-866.	0.8	27
175	Extracellular metabolites in the cortex and hippocampus of epileptic patients. Annals of Neurology, 2005, 57, 226-235.	2.8	255
176	Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology, 2005, 179, 303-309.	1.5	255
177	Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology, 2005, 179, 136-143.	1.5	33
178	Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder. Psychopharmacology, 2005, 183, 308-313.	1.5	148
179	A paradigm to investigate the self-regulation of cocaine administration in humans. Psychopharmacology, 2005, 180, 436-446.	1.5	33
180	Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence. Journal of Dual Diagnosis, 2005, 1, 37-47.	0.7	5

#	Article	IF	CITATIONS
181	Baseline and Modulated Acoustic Startle Responses in Adolescent Girls With Posttraumatic Stress Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2005, 44, 807-814.	0.3	42
182	Sex, GABA, and nicotine: The impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biological Psychiatry, 2005, 57, 44-48.	0.7	111
183	Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry, 2005, 57, 594-608.	0.7	524
184	Temporoparietal Transcranial Magnetic Stimulation for Auditory Hallucinations: Safety, Efficacy and Moderators in a Fifty Patient Sample. Biological Psychiatry, 2005, 58, 97-104.	0.7	244
185	Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial. Biological Psychiatry, 2005, 58, 424-428.	0.7	344
186	Impaired GABA Neuronal Response to Acute Benzodiazepine Administration in Panic Disorder. American Journal of Psychiatry, 2004, 161, 2186-2193.	4.0	105
187	Addition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response. Neuropsychopharmacology, 2004, 29, 1166-1171.	2.8	79
188	The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis. Neuropsychopharmacology, 2004, 29, 1558-1572.	2.8	895
189	Subtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients With Major Depression. Archives of General Psychiatry, 2004, 61, 705.	13.8	704
190	Move Over ANOVA. Archives of General Psychiatry, 2004, 61, 310.	13.8	1,227
191	Altered NMDA Glutamate Receptor Antagonist Response in Individuals With a Family Vulnerability to Alcoholism. American Journal of Psychiatry, 2004, 161, 1776-1782.	4.0	128
192	Transcranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations. Archives of General Psychiatry, 2003, 60, 49.	13.8	462
193	Posttraumatic Stress Disorder and Substance Use in Inner-City Adolescent Girls. Journal of Nervous and Mental Disease, 2003, 191, 714-721.	0.5	58
194	Cortical Î <sup>3</sup> -Aminobutyric Acid Levels Across the Menstrual Cycle in Healthy Women and Those With Premenstrual Dysphoric Disorder. Archives of General Psychiatry, 2002, 59, 851.	13.8	338
195	Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression. Psychiatry Research, 2002, 113, 245-254.	1.7	88
196	A Correlated Probit Model for Joint Modeling of Clustered Binary and Continuous Responses. Journal of the American Statistical Association, 2001, 96, 1102-1112.	1.8	137
197	Maternal Sertraline Treatment and Serotonin Transport in Breast-Feeding Mother-Infant Pairs. American Journal of Psychiatry, 2001, 158, 1631-1637.	4.0	113
198	Effect of Teenage Pregnancy on Educational Disabilities in Kindergarten. American Journal of Epidemiology, 2001, 154, 212-220.	1.6	31